Haima Therapeutics

Haima Therapeutics’ synthetic platelet technology provides hemostasis for traumatic bleeding and treats certain blood disorders. The company’s lead product, SynthoPlate, renders rapid hemostasis in a dose dependent fashion comparable to natural platelets in the acute bleeding setting.

Stage: Preclinical

News: Haima Therapeutics, a CWRU Spinoff, Funded by Department of Defense